Disc Medicine price target raised to $90 from $79 at Stifel

Stifel analyst Benjamin Burnett raised the firm’s price target on Disc Medicine (IRON) to $90 from $79 and keeps a Buy rating on the shares. Following the company’s full pipeline review, the firm came away believing that bitopertin has “a high likelihood of being granted accelerated approval,” setting up a near-term commercial opportunity, and secondly that DISC-0974 appears effective in myelofibrosis patients regardless of underlying JAKi use, the analyst tells investors.